Glucagon
Approved · EMAAlso known as Baqsimi, Gvoke, GlucaGen, Glucagone+1 more
Baqsimi, Gvoke, GlucaGen, Glucagone, Glucagonum.
Recent clinical, regulatory, research and industry developments relating to this drug.
Recall (Not Yet Classified): GLUCAGON
Role of Hyperinsulinemia in NAFLD: Dexamethasone-Pancreatic Clamp Pilot & Feasibility Study
Human Models of Selective Insulin Resistance: Pancreatic Clamp
GLP-1, GIP, and Glucagon Agonists for Obesity Treatment: A Hunger Perspective.
Glucagon resistance and metabolic-associated steatotic liver disease: a review of the evidence.
Neuronal glucose sensing mechanisms and circuits in the control of insulin and glucagon secretion.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Ogluo is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.
Evidence ↗Indication: Baqsimi is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 4 years and over with diabetes mellitus.
Evidence ↗Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- The Journal of clinical investigation4
- Diabetes2
- Diabetologia2
- Endocrinology2
- International journal of molecular sciences2
- The Journal of endocrinology2
- Holst JJ5
- Drucker DJ4
- Heimesaat MM2
- Knop FK2
- Knudsen JG2
- Nauck MA2
- Thorens B2
- Acreman S1
- University of Copenhagen4
- Center for Clinical Metabolic Research2
- Center for Integrative Genomics2
- Department of Clinical Medicine2
- Steno Diabetes Center Copenhagen2
- Allegheny General Hospital1
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 21 of the same disease areas as Glucagon in the shared literature.
Studied across 13 of the same disease areas as Glucagon in the shared literature.
Studied across 9 of the same disease areas as Glucagon in the shared literature.
Studied across 8 of the same disease areas as Glucagon in the shared literature.
Studied across 5 of the same disease areas as Glucagon in the shared literature.
Studied across 5 of the same disease areas as Glucagon in the shared literature.
Studied across 2 of the same disease areas as Glucagon in the shared literature.
Studied across 2 of the same disease areas as Glucagon in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.